The Siren Song of Weight Loss Stocks: A Cautionary Tale for Investors The allure of Viking Therapeutics' VK2735, a potential blockbuster weight loss drug, has sent Wall Street analysts into a frenzy.
With its stock plummeting to what some see as a buying opportunity, investors are being asked to take a leap of faith on this company's lead drug candidate.
Wall Street's consensus price target for Viking Therapeutics is $91, representing a 150% return from its current price.